ESR1 and triple-negative breast carcinoma: In our further subgroup analysis, IORT was more suitable for patients >55 years old, with T1, N0, ER positive, PR positive, non‐triple negative breast cancer, and grade I‐II histology, also consistent with the patients enrolled in the TARGIT‐A study.